Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival

详细信息    查看全文

• 作者：Kai-Lin Chen ; Jie Chen ; Hui-Lan Rao ; Ying Guo ; Hui-Qiang Huang…
• 关键词：Diffuse large B ; cell lymphoma ; Hepatitis ; Hepatitis B virus reactivation ; Resolved hepatitis B
• 刊名：Chinese Journal of Cancer
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：34
• 期：3
• 全文大小：773KB
• 参考文献：1.Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733鈥?5.CrossRef PubMed
  2.Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235鈥?2.CrossRef PubMed
  3.Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379鈥?1.CrossRef PubMed
  4.Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605鈥?1.CrossRef PubMed
  5.Shih LN, Sheu JC, Wang JT, Huang GT, Yang PM, Lee HS, et al. Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction. J Med Virol. 1990;32:257鈥?0.CrossRef PubMed
  6.Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170鈥?0.PubMed Central CrossRef PubMed
  7.Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89:255鈥?2.CrossRef PubMed
  8.European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167鈥?5.CrossRef
  9.Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59鈥?8.CrossRef PubMed
  10.Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90:1219鈥?3.CrossRef PubMed
  11.Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20:2013鈥?.CrossRef PubMed
  12.Ji D, Cao J, Hong X, Li J, Wang J, Chen F, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol. 2010;85:243鈥?0.CrossRef PubMed
  13.Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. 2010;116:4769鈥?6.CrossRef PubMed
  14.Swerdlow SHCE, Harris NL, Jaffe ES, Stein H, Thiele J, et al. World health organization classification of tumours of the haematopoietic and lymphoid tissues. Pileri SA: IARC Press; 2008.
  15.Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927鈥?4.CrossRef PubMed
  16.Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182鈥?.PubMed
  17.Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373鈥?0.CrossRef PubMed
  18.Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187鈥?20.
  19.Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin鈥檚 lymphoma. Haematologica. 2006;91:554鈥?.PubMed
  20.Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer. 2007;109:1360鈥?.CrossRef PubMed
  21.Kim JH, Bang YJ, Park BJ, Yoo T, Kim CW, Kim TY, et al. Hepatitis B virus infection and B-cell non-Hodgkin鈥檚 lymphoma in a hepatitis B endemic area: a case鈥揷ontrol study. Jpn J Cancer Res. 2002;93:471鈥?.CrossRef PubMed
  22.Qin XT, Lu Y, Chen XQ, Xu HP, Fan HJ. Correlation of hepatitis B virus infection to non-Hodgkin鈥檚 lymphoma. Chin J Cancer. 2007;26:294鈥?.
  23.Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11:827鈥?4.PubMed Central CrossRef PubMed
  24.Wang F, Yuan S, Teng KY, Garcia-Prieto C, Luo HY, Zeng MS, et al. High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance. Eur J Cancer Prev. 2012;21:261鈥?.CrossRef PubMed
  25.Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397鈥?08.CrossRef PubMed
  26.Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156鈥?5.CrossRef PubMed
  27.Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18:877鈥?3.CrossRef PubMed
  28.Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092鈥?00.CrossRef PubMed
  29.Chemin I, Jeantet D, Kay A, Trepo C. Role of silent hepatitis B virus in chronic hepatitis B surface antigen(鈭? liver disease. Antiviral Res. 2001;52:117鈥?3.CrossRef PubMed
  30.Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245:194鈥?05.CrossRef PubMed
  31.Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960鈥?.CrossRef PubMed
  32.Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924鈥?0.CrossRef PubMed
  33.Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004;83:769鈥?4.CrossRef PubMed
  34.Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf. 2005;4:599鈥?08.CrossRef PubMed
  35.Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother. 2005;11:189鈥?1.CrossRef PubMed
  36.Li YH, He YF, Wang FH, Lin XB, Xia ZJ, Sun XF, et al. Clinical analysis of liver damage of 116 malignant lymphoma patients with chronic HBV infection after cytotoxic chemotherapy. Chin J Cancer. 2005;24:1507鈥?.
  37.Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer. 2010;116:115鈥?1.PubMed
  38.Chinese Society of Hematology, CMA, Committee of Malignant Lymphoma, Chinese Anti-cancer Association, Chinese Society of Hepatology, CMA. Consensus on the management of lymphoma with HBV infection. Zhonghua Xue Ye Xue Za Zhi. 2013;34:988鈥?3 [in Chinese]
  39.Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714鈥?2.CrossRef PubMed
  40.Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765鈥?2.CrossRef PubMed
  41.Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol. 1997;8 Suppl 1:107鈥?.CrossRef PubMed
  
• 作者单位：Kai-Lin Chen (1) (2)
  Jie Chen (3)
  Hui-Lan Rao (1) (4)
  Ying Guo (1) (5)
  Hui-Qiang Huang (1) (2)
  Liang Zhang (6)
  Jian-Yong Shao (1) (7)
  Tong-Yu Lin (1) (2)
  Wen-Qi Jiang (1) (2)
  De-Hui Zou (8) (9)
  Li-Yang Hu (1) (2)
  Michael Lucas Wirian (1) (2)
  Qing-Qing Cai (1) (2)
  
  1. Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, Guangdong, P. R. China
  2. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China
  3. Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Radiotherapy Department, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, 510120, Guangdong, P. R. China
  4. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China
  5. Clinical Trial Center, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China
  6. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA
  7. Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China
  8. Lymphoma and Myeloma Center, Institute of Hematology and Blood Diseases Hospital, Tianjin, P. R. China
  9. State Key Lab of Experimental Method of Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, 300020, P. R. China
  
• 刊物类别：Oncology;
• 刊物主题：Oncology;
• 出版者：BioMed Central
• ISSN：1944-446X

文摘

Introduction Hepatitis B virus (HBV) reactivation has been reported in B-cell lymphoma patients with resolved hepatitis B (hepatitis B surface antigen [HBsAg]-negative and hepatitis B core antibody [HBcAb]-positive). This study aimed to assess HBV reactivation and hepatitis occurrence in diffuse large B-cell lymphoma (DLBCL) patients with resolved hepatitis B receiving rituximab-containing chemotherapy compared with HBsAg-negative/HBcAb-negative patients to identify risk factors for HBV reactivation and hepatitis occurrence and to analyze whether HBV reactivation and hepatitis affect the survival of DLBCL patients with resolved hepatitis B.